|
Chapter 1. Executive Summary
Chapter 2. An Introduction to Alzheimer's Disease
2.1 Introduction
2.2 Symptoms and Differential Diagnosis
2.3 The Risk Factors for AD
2.4 Type of Protein as a Cause for AD?
2.4.1 Neuronal and Synaptic Loss of AD
2.4.2 Chromosomal Mutations of AD
2.4.3 Inflammation of AD
2.4.4 Using brain scans to detect Alzheimer's
2.5 The Demographics for AD
2.6 Financial Burden of AD
Chapter 3. Pharmacotherapy for Alzheimer's Disease
3.1 Current AD Pharmaceutical Drug Therapies
3.2 Acetylcholinesterase Drugs - How do you Treat Mild to Moderate AD?
3.2.1 Pfizer/Eisai Aricept (Donepezil hyrdochloride) - The leading drug choice
for AD
3.2.1 Aricept clinical data
3.2.1.1 Pre-clinical data
3.2.1.2 Aricept clinical data outcomes
3.2.1.3 Eisai and Pfizer Aricept post marketing research for AD
3.2.1.4 Eisai severe Alzheimer's disease trials
3.3 Novartis Excelon (Rivastigamine) - Popular Drug Therapy for AD
3.3.1 Excelon mild-to-moderately severe Alzheimer's disease clinical data
3.3.2 J&J/ Shire Razadyne (Galantamine) is a Mild-to-moderate Treatment for AD
3.3.3 J&J/ Shire Reminyl (Galantamine) clinical studies
3.3.4 Forest and Lundbeck (Namenda/Ebixa) The Drug Treatments for Moderate to
Severe AD
3.3.4.1 Lundbeck Ebixa (Namenda) severe Alzheimer's disease clinical data
3.3.4.2 Lundbeck Ebixa (Namenda) mild-to-moderate Alzheimer's disease clinical
data
3.3.5 Comparative efficacy of Clinical Approved AD drugs
3.3.6 Cognex (Tacrine)
3.3.7 Non steroidal anti-inflammatory drugs (NSAIDs)
3.4 Comorbid Conditions
3.5 Depression associated with Alzheimer's disease and its management
Chapter 4. UK Alzheimer's Disease treatment guidelines
4.1 UK-National Institute for Clinical Excellence guidelines
4.2 NICE 2001 AD guideline
4.2.1 NICE reversal to 2001 AD guidance
4.2.2 Stakeholders' reaction to NICE 2001 AD guidelines reversal
4.2.3 NICE 2006 AD Guidance Review- Aricept, Razadyne, Exelon and Memantine
4.2.4 Judicial Review of NICE guideline 2007
Chapter 5. Global AD market
5.1 Overview of Global AD market and Geographical analysis
5.2 US Alzheimer's disease market
5.3 US AD Market Drivers and Restraints
5.3.1 Market Drivers
5.3.2 Market Restraints
5.4 Japan Alzheimer's disease Market
5.5 Japan Market Drivers and Restraints
5.5.1 Market Drivers
5.5.2 Market Restraints
5.6 France Alzheimer's disease Market
5.7 France AD Market Drivers and Restraints
5.7.1 Market Drivers
5.7.2 Market Restraints
5.8 Germany Alzheimer's disease Market
5.9 Germany AD Market Drivers and Restraints
5.9.1 Market Drivers
5.9.2 Market Restraints
5.10 UK Alzheimer's disease Market
5.11 UK AD Market Drivers and Restraints
5.11.1 Market Drivers
5.11.2 Market Restraints
5.12 Italy's Alzheimer's disease Market
5.13 Italy AD Market Drivers and Restraints
5.13.1 Market Drivers
5.13.2 Market Restraints
5.14 Spain's Alzheimer's disease Market
5.15 Spain AD Market Drivers and Restraints
5.15.1 Market Drivers
5.15.2 Market Restraints
Chapter 6. Key players in Alzheimer's Disease Pharmacotherapy
6.1 Eisai/Pfizer's Aricept
6.1.1 Eisai Aricept product expansion
6.1.2 Eisai R&D
6.2 Forest Laboratories Namenda /Lundbeck
Ebixa product expansion
6.3 Shire Razadyne product expansion
6.4 Novartis Exelon product expansion
6.4.1 Novartis Exelon TransdermalPatch for AD
6.4.2 Potential Success of Exelon Transdermal Patch
6.4.3 Novartis' Exelon and Forest Namenda combinatorial study
6.5 Will there be generic competition?
6.6 Market growth indications
Chapter 7. Alzheimer's disease R&D and pipeline
7.1 Unmet medical needs for Alzheimer's disease
7.2 Present clinical approaches to delivering AD therapies
7.2.1 Biomarkers a prospective diagnostic tool
7.3 Overview of pipeline products
7.3.1 Pipeline Drugs for AD
7.3.2 Neurochem's Alzhemed (anti-amyloid compound) illuminates strong
therapeutic potential
7.3.3 Forest's Neramexane potential follow-on product for Namenda
7.3.4. Other compounds presently in the pipeline
7.3.4.1 PBT-1 (Coloquinol)
7.3.4.2 Phenserine
7.3.4.3 Allon Therapeutics'AL-108 and AL-208 to inhibit neuronal death
7.3.4.4 Martek's DHA reduces brain lesions in AD animal models
7.3.4.5 Phytopharm Cogane -an orally active neuroprotective compound
7.3.4.6 Nicotine Replacement Therapy as a Potential Treatment for AD
7.4 Emerging Therapies for Alzheimer's disease
7.4.1 Vitamin E (Antioxidants) for AD
7.4.2 Research has revealed that Vitamin E, Vitamin C and other health foods
possess oxidative properties.
7.4.3 OTC Ginko Biloba May Slow AD Symptoms
7.4.4 Oestrogen HRT May Protect Against AD
Chapter 8. Conclusions
8.1 Expansion of Global Population
8.2 Prevalence of Alzheimer's disease in the Major Markets
8.3 FDA Approved Alzheimer's disease Therapies and NICE's
Cost-Effective Analysis
8.4 Alzheimer's disease Drug Sales across Major Markets 2006
8.5 Barriers to Generic entrants
8.6 Alzheimer's disease Revenue ($m) Forecast
8.7 Leading Companies with Products in late-stage Alzheimer's disease Pipeline
Tables
Table 1.1 Prevalence of AD Accross The Seven Major Markets (2006)
Table 1.2. AD Revenue Forecast ($m) for Seven Major Markets,2007-2012,2017 &
2022
Table 1.3 SWOT Analysis on Alzheimer's disease market
Table 2.1 Prevalence of AD 2006-2050 In Three Geographical Regions
Table 3.1 Assessment Scale for Defining Magnitude of AD
Table 3.1 contn'd Assessment Scale for defining magnitude of AD
Table 3.2 Summary of AD drugs clinical data
Table 3.3 SSRIs Considered in Managing Depression in AD
Table 3.4 Atypical antipsychotic agents considered in managing depression in AD
Table 3.5 Typical antipsychotic agents considered in managing depression in AD
Table 3.6 Anxiolytic Drugs Benzodiazepines Considered in Managing Depression in
AD
Table 3.7 Mood-Stabilizing (anti-agitation) Drugs Considered in Managing
Depression in AD
Table 5.1 The Global AD Market, 2004-2006
Table 5.2 Sales for AD Therapies in the US, 2003-2006
Table 5.3 US AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
Table 5.4 J apan AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
Table 5.5 Sales Revenues of AD Agents in France, 2003-2006
Table 5.6 France AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
Table 5.7 Sales Revenues for AD Therapies in Germany, 2003-2006
Table 5.8 Germany AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
Table 5.9 Sales Revenues for AD Therapies in the UK, 2003-2006
Table 5.10 UK AD sales revenue forecast ($m), 2007-2012,2017 & 2022
Table 5.11 Italy's Sales Revenues for AD Therapies, 2003-2006
Table 5.12 Italy AD Sales Revenue Forecast ($m), 2007-2012,2017 & 2022
Table 5.13 Spain Sales Revenues for AD Therapies, 2003-2006
Table 5.14 Spain AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
Table 6.1 Summary of Aricepts Approved indications for AD
Table 6.2 Present Aricept Extra indications in Major Markets
Table 6.3 Patent Expiration on leading AD products in Major Markets
Table 7.1 Alzheimer's disease phase III Pipeline
Table 7.2 Alzheimer's disease phase II Pipeline
Table 7.3 Alzheimer's disease phase I Pipeline
List of Charts
Chart 1.1. Demographics of Alzheimer's Disease Across Major Markets, 2006
Chart 1.2. Aricept Total Sales Revenue Across Seven Major Markets, 2006
Chart 1.3. Memantine Total Sales Revenue Across Six Major Markets, 2006
Chart 1.4. Razadyne (previously Reminyl) Total Sales Revenue Across Six Major
Markets, 2006
Chart 1.5. Exelon Total Sales Revenue Across Six Major Markets, 2006
Chart 2.1. Current and Projected Global Prevalence of Alzheimer's Disease
Chart 2.2 Global Cost of AD During 2003-2005 ($bn)
Chart 5.1 The Global Sales ($m) of AD drugs, 2004-2006
Chart 5.2 The Global Market Share for Leading AD Drugs, 2006
Chart 5.3 Sales for AD Therapies in the US, 2003-2006
Chart 5.4 Market Share for AD agents in the US, 2006
Chart 5.5 US AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
Chart 5.6 Aricept Sales Revenue,2003-2006
Chart 5.7 Japan AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
Chart 5.8 Sale Revenues of AD Agents in France, 2003-2006
Chart 5.9 Market Share for AD Agents in France,2006
Chart 5.10 France AD Sales revenue Forecast ($m), 2007-2012, 2017 & 2022
Chart 5.11 Sales Revenues for AD Therapies in Germany, 2003-2006
Chart 5.12 Market Share for AD Agents in Germany,2006
Chart 5.13 Germany AD Sales Revenue Forecast ($m), 2007-2012,2017 & 2022
Chart 5.14 Sales Revenues for AD Therapies in the UK, 2003-2006
Chart 5.15 Market Share for AD Agents in the UK, 2006
Chart 5.16 UK AD Sales Revenue Forecast ($m), 2007-2012,2017 & 2022
Chart 5.17 Sales Revenues for AD Therapies in Italy, 2003-2006
Chart 5.18 Market Share for AD Agents in Italy,2006
Chart 5.19 Italy AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
Chart 5.20 Market Share for AD Agents in Spain, 2006
Chart 5.21 Market Share for AD Agents in Spain, 2006
Chart 5.22 Spain AD Sales Revenue Forecast ($m), 2007-2012, 2017 & 2022
Companies mentioned in this report include:
Abbott
Acambis
Accera
Aeolus
Affiris
Allon Therapeutics
Antigenics
AstraZeneca
Athenagen
Avera
Barr Pharmaceuticals
Bayer
BTG
CAD
Cell Genesys
Ceregene
Chiesi
CoMentis
Cortex
Cytos
Dae Wong
Daiichi Sankyo
Debiopharm
DebioPharma
Ebewe's
Eisai
Elan
Eli Lilly
Encore
Enkam
Epix Pharma
Evotec
First Horizon
Florida University
Forest
GelTex
Genzyme
Helicon Inflazyme
Hunter-Fleming
Inflazyme
Intellect Neuroscience
J&J
Janssen
Loyola Medical School
Lundbeck
Martek
Memory
Merck Serono
Merz
Migenix
Myriad
Neurochem
Neuro-Hitech
Neuropharma
Newron
New York University
NicOx
Nippon Kayaku
Novartis
Nymox
Ono
Otsuka
Pfizer
Pharmexa
Pierre Fabre
Prana Technology
Procter and Gamble
Progenics
Roche
Sagittarius
Sanofi Pasteur
Sanofi-Aventis
Shanghai Institute
Shire
Sloan Kettering
Synaptech
Taiho
Teva
The Stanley Medical
Torrey Pines Therapeutics
Toyama
Transition
UCB
UK- National Institute of Clinical Excellence (NICE)
University of Califonia
University of South Alabama
US Department of Health
Vasogen
Vernalis
Wyeth
|